| |
Rescue studies are not meant to be taken lightly – logistical hurdles and communication challenges are aplenty. Despite this, Premier Research doesn’t back down. See how our unique advantages helped a sponsor recover a Phase 1 oncology trial: Learn More
Premier Research. Built for Biotech℠ 
|
|
Today’s Big NewsOct 13, 2023 |
| By James Waldron Roche has claimed the latest phase 2 readout for its multiple sclerosis drug backs up the BTK inhibitor’s "best in disease" potential by achieving the "holy grail" in biopharma: crossing the blood-brain barrier. |
|
|
|
By Nick Paul Taylor Relay Therapeutics has decided to extend its race to market. Citing the impact of the Inflation Reduction Act (IRA), the biotech has paused plans to bring lirafugratinib to market in a rare cancer, choosing instead to pursue a larger, tumor-agnostic opportunity. |
By Nick Paul Taylor Sotio Biotech has dealt another blow to attempts to establish cytokines as a cornerstone of cancer care, scrapping ongoing studies of its IL-15 superagonist after seeing insufficient efficacy in the clinic. |
Sponsored by Trinity Life Sciences In a dynamic landscape, three emerging trends have the power to reshape the complexities of pharmaceutical commercialization. |
By Max Bayer CUNY is once again pinning its misfortunes on short-sellers, suggesting they were involved in leaking a CUNY report outlining scientific misconduct from a key scientific adviser. |
Sponsored by IQVIA Greg Lever, Director within the IQVIA Applied Data Science Center, reveals how modeling technology is being used to unlock value and enhance the experience of trial participants. |
By Max Bayer,Gabrielle Masson U.K.-based public health charity Wellcome has not shied away from its ambitious goal of donating 16 billion pounds sterling by 2032. Now, the organization has a new chief to oversee the mission. |
Sponsored by AnaptysBio AnaptysBio announces top-line data showing rapid clearance of generalized pustular psoriasis (GPP), a rare systemic skin disease |
By Helen Floersh Researchers have compiled the most extensive map yet of cells in the human brain, revealing new layers of complexity. |
By Ayla Ellison,Annalee Armstrong In this episode of "The Top Line," Fierce Biotech's Annalee Armstrong engages in a conversation with Howard Fillit, M.D., an expert in the field of Alzheimer's research and the co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation. They delve into the pioneering work being done in Alzheimer's research, discuss the latest breakthroughs, and explore the ongoing efforts to combat this complex disease. |
By Angus Liu Bristol Myers Squibb’s Zeposia is no longer the only S1P receptor modulator on the market for ulcerative colitis, thanks to an FDA approval for what appears to be a more effective drug from Pfizer. |
By Zoey Becker On the 1-year anniversary of the official start of the U.S. Adderall shortage, lawmakers inked a letter urging the FDA and DEA for an update detailing the progress the agencies have made in addressing the issue. |
By Angus Liu GSK has tapped Chongqing Zhifei to distribute Shingrix in China. BioNTech in-licensed a HER3 antibody-drug conjugate from Chinese company MediLink Therapeutics. The FDA rejected Biocon's proposed biosimilar version of Novo Nordisk's NovoLog—again. And more. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," Fierce Biotech's Annalee Armstrong engages in a conversation with Howard Fillit, M.D., an expert in the field of Alzheimer's research and the co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation. They delve into the pioneering work being done in Alzheimer's research, discuss the latest breakthroughs, and explore the ongoing efforts to combat this complex disease. |
|
|---|
|
|
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper Cell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] Sponsored by: Thermo Fisher Scientific |
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| Edison Ballroom, New York City |
|
|
| |
|
